The thesis
Why now, why us
The full market map, the precedent from consolidated markets, and why the next 24 months are the window.
The full picture, behind one door.
The thesis, the live traction, and the model — for investors backing the consolidation of Indian pharma. Request access and we'll be in touch quickly.
Enough to take us seriously.
The traction
Where we are today
Live corridors, acquired distributors, GMV on the network, and what Pharma OS is running in production.
The model
How it compounds
Unit economics, the acquisition playbook, the path to FY30, and where capital goes to work.